De-nol tab. p / o captivity. 120 mg No. 112
Package quantity, pcs:
32
56
112
Category
Ulcer and gastritis
,
Antacids
Scope of the drug
Gastrointestinal tract
Release form
Tablet
Manufacturer country
Russia
Package quantity, pcs
112
Release form, composition and packaging
Creamy white film-coated tablets, round, biconvex, with the inscription gbr 152" squeezed out on one side, and a graphic pattern in the form of a square with discontinuous sides and rounded corners squeezed out on the other side, odorless or slightly odorless ammonia.
1 tab.
bismuth tripotassium dicitrate
304.6 mg,
which corresponds to the content of bismuth oxide
120 mg
corn starch - 70.6 mg, povidone K30 - 17.7 mg, potassium polyacrylate - 23.6 mg, macrogol 6000 - 6 mg, magnesium stearate - 2 mg.
Shell composition: opadry OY-S-7366 (hypromellose 5 mPa s - 3.2 mg, macrogol 6000 - 1.1 mg).
8 pcs.
- blisters (4) - cardboard packs.
8 pcs.
- blisters (7) - cardboard packs.
8 pcs. - blisters (14) - packs of cardboard. Pharmacological action Anti-ulcer agent with bactericidal activity against Helicobacter pylori. It also has anti-inflammatory and astringent properties. In the acidic environment of the stomach, it forms insoluble bismuth oxychloride and citrate, and also chelates with a protein substrate in the form of a protective film on the surface of ulcers and erosions. By increasing the synthesis of prostaglandin E, the formation of mucus and the secretion of bicarbonate, it stimulates the activity of cytoprotective mechanisms, increases the resistance of the gastrointestinal mucosa to the effects of pepsin, hydrochloric (hydrochloric) acid, enzymes and bile salts. Leads to the accumulation of epidermal growth factor in the defect area. Reduces the activity of pepsin and pepsinogen. Pharmacokinetics Bismuth tripotassium dicitrate is practically not absorbed from the gastrointestinal tract.However, a small amount of bismuth can enter the systemic circulation. It is excreted mainly in the feces. An insignificant amount of bismuth entering the plasma is excreted by the kidneys. Indications for use Peptic ulcer and duodenal ulcer in the acute phase (including associated with Helicobacter pylori) chronic gastritis and gastroduodenitis in the acute phase (including associated with Helicobacter pylori) irritable bowel syndrome, which occurs predominantly with symptoms of diarrhea functional dyspepsia not associated with organic diseases of the gastrointestinal tract. Contraindications for use Severe renal dysfunction, pregnancy, lactation, hypersensitivity to bismuth tripotassium dicitrate. Dosing regimen Adults and children over 4 years of age - inside 2-4 times / day 30 minutes before meals ...The dose depends on the age of the patient.
The course of treatment is 4-8 weeks.
For the next 8 weeks, do not take bismuth-containing drugs.
For the eradication of Helicobacter pylori, it is advisable to use bismuth tripotassium dicitrate in combination with antibacterial drugs with anti-Helicobacter activity. Side effect From the digestive system: transient effects are possible - nausea, vomiting, increased stool frequency, constipation.
Dermatological reactions: skin rash, itching.
From the side of the central nervous system: with long-term use in high doses - encephalopathy associated with the accumulation of bismuth in the central nervous system. Drug interaction With the simultaneous administration of other drugs, as well as food and liquids, in particular, antacids, milk, fruit and fruit juices, it is possible to change the effectiveness of bismuth tripotassium dicitrate. Use during pregnancy and lactation. Use during pregnancy and lactation (breastfeeding) is contraindicated. Special instructions Do not use for more than 8 weeks.
During treatment, it is not recommended to exceed the established daily doses for adults and children.
At the end of the course of treatment in recommended doses, the concentration of the active substance in the blood plasma does not exceed 3-58 Ојg / l, and intoxication is observed only at a concentration of more than 100 Ојg / l.
Against the background of application, stool may turn black due to the formation of bismuth sulfide
Name ENG
De-Nol
Clinical and pharmacological group
A drug that has a protective effect on the mucous membrane of the stomach and duodenum.
Antiulcer drug
ATX code
Bismuth subcitrate
Dosage
120 mg
Structure
1 tablet contains: Active substance: bismuth tripotassium dicitrate 304.6 mg (in terms of bismuth oxide Bi2O3 - 120 mg)
Excipients: corn starch
povidone K30
potassium polyacrylate
macrogol 6000
magnesium stearate
Sheath: Opadry OY-S-7366 (hypromellose, macrogol 6000).
Indications
Peptic ulcer and duodenal ulcer in the acute phase (including associated with Helicobacter pylori)
chronic gastritis and gastroduodenitis in the acute phase (including associated with Helicobacter pylori)
irritable bowel syndrome, which occurs predominantly with symptoms of diarrhea
functional dyspepsia not associated with organic gastrointestinal diseases.
INN / Active ingredient
bismuth tripotassium dicitrate
Contraindications
Severe renal dysfunction, pregnancy, lactation, hypersensitivity to bismuth tripotassium dicitrate.
Storage conditions and periods
The drug should be stored at temperatures between 15 В° and 25 В° C.
Shelf life 4 years.
Specifications
Category
Ulcer and gastritis
,
Antacids
Scope of the drug
Gastrointestinal tract
Release form
Tablet
Manufacturer country
Russia
Package quantity, pcs
112
Scope of application
Gastroenterology
Minimum age from
4 years old
Way of introduction
Through the mouth
Vacation conditions
Without recipe
Brand name
ASTELLAS
The amount of the dosage form in the primary package
8 pcs.
Primary packaging type
Blister
Type of consumer packaging
Pack of cardboard
Pharmaco-therapeutic group
Antiseptic intestinal and astringent
Anatomical and therapeutic characteristics
A02BX05 Bismuth tripotassium dicitrate
Dosage form
Film-coated tablets
The target audience
Children
Expiration date in days
48
Package weight, g
65
Mode of application
:
Inside, with a little water. < br> Adults and children over 12 years old - 1 tablet 4 times a day 30 minutes before meals and at night or 2 tablets 2 times a day 30 minutes before meals. < Br > Children from 8 to 12 years old - 1 tablet 2 times a day 30 minutes before meals. < br> Children from 4 to 8 years old - at a dose of 8 mg / kg / day
the daily dosage is divided into 2 doses.
Take 30 minutes before meals. < br> Duration of treatment - 4-8 weeks.
For the next 8 weeks, do not use preparations containing bismuth. < br> For the eradication of Helicobacter pylori, it is advisable to use De-Nol in combination with other antibacterial agents with anti-Helicobacter activity.
Dosage (volume) of the substance in the preparation
:
Bismuth tripotassium dicitrate 304.6 mg (in terms of bismuth oxide Bi2O3 - 120 mg)
Information on technical characteristics, delivery set, country of manufacture "